바이오테크놀러지 및 제약 서비스 아웃소싱 시장 조사 리포트 : 서비스, 최종사용자, 지역별 - 세계 예측(-2027년)과 COVID-19의 누적 영향

The Global Biotechnology & Pharmaceutical Services Outsourcing Market size was estimated at USD 121.90 billion in 2021 and expected to reach USD 135.51 billion in 2022, and is projected to grow at a CAGR 11.42% to reach USD 233.29 billion by 2027.

Market Statistics:

The report provides market sizing and forecast across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Biotechnology & Pharmaceutical Services Outsourcing to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Services, the market was studied across Auditing & Assessment, Consulting, Product Design & Development, Product Maintenance, Product Testing & Validation, Regulatory Affairs, and Training & Education. The Consulting is further studied across Quality Management Systems Consulting, Regulatory Compliance, and Remediation. The Regulatory Affairs is further studied across Clinical Trial Applications & Product Registration, Legal Representation, and Regulatory Writing & Publishing.

Based on End-User, the market was studied across Biotech Companies and Pharmaceutical Companies.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:

We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Biotechnology & Pharmaceutical Services Outsourcing market considering the current update on the conflict and its global response.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Biotechnology & Pharmaceutical Services Outsourcing Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor's strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Biotechnology & Pharmaceutical Services Outsourcing Market, including Charles River Laboratories, Concept Heidelberg GmbH, Covance Inc., Geographic Foothold, GMP Pharmaceuticals Pty Ltd., ICON plc, IQVIA HOLDINGS, INC., Lachman Consultant Services, Inc., NSF International, Parexel International Corporation, PRA Health Sciences, Quality Context Ltd, Reading Scientific Service Ltd, Service Benchmarking, and The Quantic Group.

The report provides insights on the following pointers:

• 1. Market Penetration: Provides comprehensive information on the market offered by the key players
• 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
• 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
• 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
• 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

• 1. What is the market size and forecast of the Global Biotechnology & Pharmaceutical Services Outsourcing Market?
• 2. What are the inhibiting factors and impact of COVID-19 shaping the Global Biotechnology & Pharmaceutical Services Outsourcing Market during the forecast period?
• 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Biotechnology & Pharmaceutical Services Outsourcing Market?
• 4. What is the competitive strategic window for opportunities in the Global Biotechnology & Pharmaceutical Services Outsourcing Market?
• 5. What are the technology trends and regulatory frameworks in the Global Biotechnology & Pharmaceutical Services Outsourcing Market?
• 6. What is the market share of the leading vendors in the Global Biotechnology & Pharmaceutical Services Outsourcing Market?
• 7. What modes and strategic moves are considered suitable for entering the Global Biotechnology & Pharmaceutical Services Outsourcing Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Limitations
• 1.7. Assumptions
• 1.8. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing R&D expenditure of pharmaceutical and biopharmaceutical industry
    • 5.1.1.2. Rising demand for outsourcing services in drug development
    • 5.1.1.3. Growing regulatory support activities including labeling and documentation
  • 5.1.2. Restraints
    • 5.1.2.1. Issues associated with monitoring and lack of standardization
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising outsourcing of generics and biosimilar manufacturing
    • 5.1.3.2. Outsourcing of clinical trial activity
  • 5.1.4. Challenges
    • 5.1.4.1. Issues associated with data security and increasing lead time and logistics costs
• 5.2. Cumulative Impact of COVID-19

6. Biotechnology & Pharmaceutical Services Outsourcing Market, by Services

• 6.1. Introduction
• 6.2. Auditing & Assessment
• 6.3. Consulting
  • 6.4.1. Quality Management Systems Consulting
  • 6.4.2. Regulatory Compliance
  • 6.4.3. Remediation
• 6.4. Product Design & Development
• 6.5. Product Maintenance
• 6.6. Product Testing & Validation
• 6.7. Regulatory Affairs
  • 6.8.1. Clinical Trial Applications & Product Registration
  • 6.8.2. Legal Representation
  • 6.8.3. Regulatory Writing & Publishing
• 6.8. Training & Education

7. Biotechnology & Pharmaceutical Services Outsourcing Market, by End-User

• 7.1. Introduction
• 7.2. Biotech Companies
• 7.3. Pharmaceutical Companies

8. Americas Biotechnology & Pharmaceutical Services Outsourcing Market

• 8.1. Introduction
• 8.2. Argentina
• 8.3. Brazil
• 8.4. Canada
• 8.5. Mexico
• 8.6. United States

9. Asia-Pacific Biotechnology & Pharmaceutical Services Outsourcing Market

• 9.1. Introduction
• 9.2. Australia
• 9.3. China
• 9.4. India
• 9.5. Indonesia
• 9.6. Japan
• 9.7. Malaysia
• 9.8. Philippines
• 9.9. Singapore
• 9.10. South Korea
• 9.11. Taiwan
• 9.12. Thailand
• 9.13. Vietnam

10. Europe, Middle East & Africa Biotechnology & Pharmaceutical Services Outsourcing Market

• 10.1. Introduction
• 10.2. Denmark
• 10.3. Egypt
• 10.4. Finland
• 10.5. France
• 10.6. Germany
• 10.7. Israel
• 10.8. Italy
• 10.9. Netherlands
• 10.10. Nigeria
• 10.11. Norway
• 10.12. Poland
• 10.13. Qatar
• 10.14. Russia
• 10.15. Saudi Arabia
• 10.16. South Africa
• 10.17. Spain
• 10.18. Sweden
• 10.19. Switzerland
• 10.20. Turkey
• 10.21. United Arab Emirates
• 10.22. United Kingdom

11. Competitive Landscape

• 11.1. FPNV Positioning Matrix
  • 11.1.1. Quadrants
  • 11.1.2. Business Strategy
  • 11.1.3. Product Satisfaction
• 11.2. Market Ranking Analysis, By Key Player
• 11.3. Market Share Analysis, By Key Player
• 11.4. Competitive Scenario
  • 11.4.1. Merger & Acquisition
  • 11.4.2. Agreement, Collaboration, & Partnership
  • 11.4.3. New Product Launch & Enhancement
  • 11.4.4. Investment & Funding
  • 11.4.5. Award, Recognition, & Expansion

12. Company Usability Profiles

• 12.1. Charles River Laboratories
  • 12.1.1. Business Overview
  • 12.1.2. Key Executives
  • 12.1.3. Product & Services
• 12.2. Concept Heidelberg GmbH
  • 12.2.1. Business Overview
  • 12.2.2. Key Executives
  • 12.2.3. Product & Services
• 12.3. Covance Inc.
  • 12.3.1. Business Overview
  • 12.3.2. Key Executives
  • 12.3.3. Product & Services
• 12.4. Geographic Foothold
  • 12.4.1. Business Overview
  • 12.4.2. Key Executives
  • 12.4.3. Product & Services
• 12.5. GMP Pharmaceuticals Pty Ltd.
  • 12.5.1. Business Overview
  • 12.5.2. Key Executives
  • 12.5.3. Product & Services
• 12.6. ICON plc
  • 12.6.1. Business Overview
  • 12.6.2. Key Executives
  • 12.6.3. Product & Services
• 12.7. IQVIA HOLDINGS, INC.
  • 12.7.1. Business Overview
  • 12.7.2. Key Executives
  • 12.7.3. Product & Services
• 12.8. Lachman Consultant Services, Inc.
  • 12.8.1. Business Overview
  • 12.8.2. Key Executives
  • 12.8.3. Product & Services
• 12.9. NSF International
  • 12.9.1. Business Overview
  • 12.9.2. Key Executives
  • 12.9.3. Product & Services
• 12.10. Parexel International Corporation
  • 12.10.1. Business Overview
  • 12.10.2. Key Executives
  • 12.10.3. Product & Services
• 12.11. PRA Health Sciences
  • 12.11.1. Business Overview
  • 12.11.2. Key Executives
  • 12.11.3. Product & Services
• 12.12. Quality Context Ltd
  • 12.12.1. Business Overview
  • 12.12.2. Key Executives
  • 12.12.3. Product & Services
• 12.13. Reading Scientific Service Ltd
  • 12.13.1. Business Overview
  • 12.13.2. Key Executives
  • 12.13.3. Product & Services
• 12.14. Service Benchmarking
  • 12.14.1. Business Overview
  • 12.14.2. Key Executives
  • 12.14.3. Product & Services
• 12.15. The Quantic Group
  • 12.15.1. Business Overview
  • 12.15.2. Key Executives
  • 12.15.3. Product & Services

13. Appendix

• 13.1. Discussion Guide
• 13.2. License & Pricing